BEXSERO multicomponent meningococcal B vaccine (recombinant, adsorbed) is a vaccine for the prevention of invasive meningococcal group B disease caused by Neisseria meningitidis group B bacteria (germs). These germs can cause invasive meningococcal group B disease (also known as Meningitis B) which can lead to serious, and sometimes life-threatening, infections such as meningitis (infection of the lining of the brain and spinal cord) and sepsis (blood poisoning). BEXSERO is given to individuals from 2 months through 25 years of age. As with any vaccine, BEXSERO may not fully protect all of those who are vaccinated. BEXSERO does not treat or reduce the consequences of meningococcal meningitis, including meningitis, sepsis, and death. Ask your healthcare professional if BEXSERO is right for your child. Full product information can be found at http://gsk.ca/bexsero/en. To report an adverse event, please call 1-800-387-7374.
For information about how GSK uses, shares, and protects personal information, including information collected online, please read GSK's Privacy Statement.
Please note: This site does not provide medical advice. The contents of this site are for information purposes only and are not in any way intended to replace or substitute the advice of your healthcare professional. Your healthcare professional is the best source of information regarding your health. This digital channel is not intended as a means for reporting an adverse event (side effect) or complaint for any GlaxoSmithKline product. To report an adverse event or product complaint, please call 1-800-387-7374. This site is intended for use by Canadian residents only.